Patents by Inventor Yoshiyuki Taoda

Yoshiyuki Taoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11814368
    Abstract: The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: November 14, 2023
    Assignees: SHIONOGI & CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuki Tachibana, Shota Uehara, Yuto Unoh, Kenji Nakahara, Yoshiyuki Taoda, Yukiko Yamatsu, Shigeru Ando, Michihito Sasaki
  • Publication number: 20230227454
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 20, 2023
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshiyuki TAODA, Yuto UNOH
  • Publication number: 20230212154
    Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: , or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 6, 2023
    Applicants: Shionogi & Co., Ltd., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuki TACHIBANA, Shota UEHARA, Yuto UNOH, Kenji NAKAHARA, Yoshiyuki TAODA, Yukiko YAMATSU, Shigeru ANDO, Michihito SASAKI
  • Patent number: 11649236
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: May 16, 2023
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yoshiyuki Taoda, Yuto Unoh
  • Publication number: 20230128162
    Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula (I): wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 27, 2023
    Applicants: Shionogi & Co., Ltd., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuki TACHIBANA, Shota UEHARA, Yuto UNOH, Kenji NAKAHARA, Yoshiyuki TAODA, Koji KASAMATSU, Yukiko YAMATSU, Shigeru ANDO, Atsuhiro IIMURO, Takahiro SUTO, Michihito SASAKI
  • Publication number: 20230117695
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound. An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 20, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.
    Inventors: Akihiro ISHII, Akihiko SATO, Makoto KAWAI, Yoshiyuki TAODA
  • Patent number: 11492352
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
    Type: Grant
    Filed: June 29, 2019
    Date of Patent: November 8, 2022
    Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, SHIONOGI & CO., LTD.
    Inventors: Akihiro Ishii, Akihiko Sato, Makoto Kawai, Yoshiyuki Taoda
  • Patent number: 11453669
    Abstract: The present invention provides a compound represented by the following formula (I): wherein, ring A is a substituted or unsubstituted non-aromatic heterocycle; ring C is a benzene ring or the like; Q is a 5-membered aromatic heterocycle or the like; each R1 is independently halogen or the like; L is substituted or unsubstituted alkylene; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 27, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Yoshiyuki Taoda
  • Publication number: 20220213121
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 7, 2022
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Patent number: 11267823
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: March 8, 2022
    Assignees: SHIONOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Publication number: 20210292321
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
    Type: Application
    Filed: June 29, 2019
    Publication date: September 23, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.
    Inventors: Akihiro ISHII, Akihiko SATO, Makoto KAWAI, Yoshiyuki TAODA
  • Publication number: 20210155622
    Abstract: The present invention provides a compound represented by the following formula (I): wherein, ring A is a substituted or unsubstituted non-aromatic heterocycle; ring C is a benzene ring or the like; Q is a 5-membered aromatic heterocycle or the like; each R1 is independently halogen or the like; L is substituted or unsubstituted alkylene; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: May 30, 2019
    Publication date: May 27, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventor: Yoshiyuki TAODA
  • Publication number: 20210122751
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 29, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshiyuki TAODA, Yuto UNOH
  • Patent number: 10927129
    Abstract: The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: February 23, 2021
    Assignees: SHINOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Publication number: 20200339565
    Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
    Type: Application
    Filed: November 15, 2019
    Publication date: October 29, 2020
    Applicant: Shionogi & Co., Ltd.
    Inventors: Chika TAKAHASHI, Hidenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
  • Publication number: 20200339598
    Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20190284208
    Abstract: The present invention is to provide a novol compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X? is a single bond, a hetoro atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound; including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: May 1, 2019
    Publication date: September 19, 2019
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20190248785
    Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
    Type: Application
    Filed: November 19, 2018
    Publication date: August 15, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Chika TAKAHASHI, Hidenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
  • Publication number: 20190152990
    Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X? is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylrene in which the hetero atom group may intervene; R2 is optionally substituted aryl; Ra is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4and Z2 part taken together forms a ring, to forma polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 23, 2019
    Applicants: ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Patent number: 10202379
    Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 12, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Chika Takahashi, Hidenori Mikamiyama, Toshiyuki Akiyama, Kenji Tomita, Yoshiyuki Taoda, Makoto Kawai, Kosuke Anan, Masayoshi Miyagawa